Telescope InnovationsTELIF -3.67%33 Current Ratio is 2.59 as of May. 2026, which is 48% above its 10-year median of 1.75. GuruFocus rates TELIF with a GF Score™ of 33/100 and a GF Value™ of $0.39 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,413 Biotechnology companies, Telescope Innovations ranks worse than 61.57% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Telescope Innovations's current ratio for the quarter that ended in May. 2026 was 2.59.
Telescope Innovations has a current ratio of 2.59. It generally indicates good short-term financial strength.
The historical rank and industry rank for Telescope Innovations's Current Ratio or its related term are showing as below:
TELIF'
s Current Ratio Range Over the Past 10 Years
Min: 0.02 Med: 1.75 Max: 14.07
Current: 2.59
During the past 7 years, Telescope Innovations's highest Current Ratio was 14.07. The lowest was 0.02. And the median was 1.75.
TELIF's Current Ratio is ranked worse than 61.57% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs TELIF: 2.59
Telescope Innovations (OTCPK:TELIF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Telescope Innovations Current Ratio Related Terms
Telescope Innovations Current Ratio Historical Data
* Premium members only.
The historical data trend for Telescope Innovations's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELIF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Telescope Innovations's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telescope Innovations Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telescope Innovations's Current Ratio distribution charts can be found below:
* The bar in red indicates where Telescope Innovations's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telescope Innovations (TELIF) has a Current Ratio of 2.59 as of May. 2026. This is 48% above median its historical median of 1.75. Over the past decade, Telescope Innovations' Current Ratio has ranged from 0.02 to 14.07. According to the industry distribution chart, Telescope Innovations ranks #870 out of 1413 companies in the Biotechnology industry, placing it in the top 61.6%.
Is Telescope Innovations' Current Ratio too high?
Telescope Innovations' current Current Ratio of 2.59 is 48% above median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 14.07. The Biotechnology industry median Current Ratio is 3.89. Telescope Innovations' value of 2.59 is 33.4% below this industry median. Based on the distribution chart, Telescope Innovations ranks #870 out of 1413 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Telescope Innovations has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Telescope Innovations' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telescope Innovations ranks #870 out of 1413 companies for Current Ratio. This places Telescope Innovations in the lower half of its industry. The industry median Current Ratio is 3.89. Telescope Innovations' value of 2.59 is 33.4% below this benchmark. Historically, Telescope Innovations' own Current Ratio has ranged from 0.02 to 14.07 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 3.89, Telescope Innovations has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telescope Innovations's current Current Ratio of 2.59 is 33.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telescope Innovations's current Current Ratio is 2.59, which is 48% above median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telescope Innovations stock overvalued right now?
Based on GuruFocus' analysis, Telescope Innovations (TELIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.39, compared to a current price of $0.56 — trading 43.3% above its estimated fair value. The current Current Ratio is 2.59, which is 48% above median its 10-year median of 1.75 and 33.4% below the Biotechnology industry median of 3.89. Telescope Innovations' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Telescope Innovations (TELIF), the current Current Ratio is 2.59 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telescope Innovations (TELIF) Overvalued in 2026?
Based on GuruFocus' analysis, Telescope Innovations stock appears to be overvalued.
The current stock price of $0.56 is trading 43.3% above its estimated GF Value™ of $0.39.
GuruFocus considers Telescope Innovations to be Significantly Overvalued.
Key valuation signals for TELIF:
Current Ratio: 2.59 (48% above median its 10-year median of 1.75)
GF Value™: $0.39 vs. price of $0.56 (43.3% above fair value)
Industry Position: 33.4% below the Biotechnology median (#870 of 1413)
No single metric tells the full story. See the TELIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telescope Innovations Corp is a technology company focused on development as a Contract Research Organization (CRO) to develop intellectual property, provide contract research, and build automation products, and operates as a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. Its flagship product is the DirectInject-LC system. The Company operates in a single operating segment and generates revenue from three streams: contract research services, grant income, and the sale of automation products, with the majority of revenue derived from automation product sales from customer contracts. It operates in Canada, the United States, Europe, and Asia, with the majority of revenue coming from the United States.
33GF Score
Get the complete analysis for TELIF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELIF has been successfully added to your 
